摘要
目的对特立帕肽和地舒单抗进行Mini卫生技术评估(mini health technology assessment,Mini HTA),以期为药品遴选、临床安全合理用药提供依据。方法通过必要性、有效性、安全性、经济性、国家医保、基本药物、一致性评价、储藏条件、有效期、全球使用情况及企业信誉度等11个方面对特立帕肽和地舒单抗进行Mini HTA,结合权重值对其进行评分。结果特立帕肽和地舒单抗最终分值分别为59分和71分。二者在增加骨密度和降低骨折风险方面较安慰剂和其他药物有明显优势。均未进入医保目录,均是原研药品且在全球范围内广泛使用。经济性方面特立帕肽价格高于地舒单抗。安全性方面,特立帕肽可引起高钙血症。地舒单抗可引起低钙血症,尤其是肌酐清除率小于30 mL·min^(-1)或接受透析患者低钙血症风险会增高。结论本次Mini HTA从多维度评估药品,可为医院遴选及合理使用特立帕肽和地舒单抗提供参考。
OBJECTIVE To provide reference for drug selection or safe and rational use of drugs by Mini health technology assessment(Mini HTA)of teriparatide and denosumab.METHODS Mini HTA was conducted for evaluation of teriparatide and denosumab according to the clinical used necessity,effectiveness,safety,economy,national medical insurance drugs,national essential drugs,consistency evaluation,storage conditions,validity period,global use and enterprise reputation in 11 aspects.The values were obtained considering the weight of different indexes.RESULTS The final scores of teriparatide and denosumab were 59 and 71,respectively.These two drugs showed obvious advantages over placebo and other drugs in increasing bone mineral density and reducing fracture risk.None of them had entered national health insurance drugs,and both of them were original varieties and widely used worldwide.From the economical point of view,the price of teriparatide was more expensive than that of denosumab.In terms of safety,teriparatide could cause hypercalcemia.while denosumab led to hypocalcemia,especially the risk would enhanced in patients with creatinine clearance less than 30 mL·min^(-1)or suffering dialysis.CONCLUSION Mini HTA can provide an important reference for hospitals to select and reasonably use teriparatide and denosumab in a multi-dimensional perspective.
作者
张许
陈文文
刘燕琳
张厚莉
高洁
丁静
党和勤
ZHANG Xu;CHEN Wenwen;LIU Yanlin;ZHANG Houli;GAO Jie;DING Jing;DANG Heqin(Department of Pharmacy,the Second Affiliated Hospital of Shandong First Medical University,Tai’an,Shandong 271000,China)
出处
《今日药学》
CAS
2022年第8期611-617,共7页
Pharmacy Today
基金
山东省医药卫生科技发展计划项目(2018WS120)
山东第一医科大学学术提升计划(2019QL017)
泰安市科技创新发展项目(2020NS226)
作者简介
张许,主管药师,研究方向:药品综合评价;通信作者:党和勤,主任药师,研究方向:临床药学,E-mail:d75766@163.com
